Abstract:Chemotherapy is one of the most effective nonsurgical treatments for various types of tumor. Identifying different combinations of antitumor agents that can produce synergistic antitumor effects remains an important clinical strategy. In the present study, we showed that the combination of histone deacetylase 6 (HDAC6) inhibitor tubastatin A together with cyclooxygenase-2 (COX-2) inhibitor celecoxib resulted in synergistic antitumor effects in CAL 27 and SACC-83 cells. Treatment with celecoxib alone promoted the membrane translocation of phosphatase and tensin homolog (PTEN), indicating PTEN activation, and consequently led to protein kinase B (AKT) dephosphorylation (inactivation). Similarly, treatment with an HDAC6 inhibitor alone promoted PTEN membrane translocation and correspondingly dephosphorylated AKT. The combination of celecoxib and an HDAC6 inhibitor synergistically increased PTEN membrane translocation and inactivated AKT. Moreover, celecoxib enhanced the HDAC6 inhibitor-induced antitumor effects in PTEN-deficient U-87 MG cells that had been stably transfected with wild-type PTEN, but not in the same cell line stably transfected with mutant PTEN-K163R, which cannot be activated by HDAC6 inhibitors. In summary, the results indicated that the COX-2 inhibitor celecoxib enhanced the HDAC6 inhibitor-induced antitumor effects by activating the PTEN/AKT signaling pathway. Introduction Chemotherapy is one of the major strategies for cancer treatment, and functions by targeting the physiological characteristics of cancer cells, including proliferation, angiogenesis, apoptosis, invasion and migration (1). However, drug resistance (2) and severe side-effects (3) still hinder the effects of chemotherapy. The use of drug combinations has numerous benefits for cancer therapy. It enhances the therapeutic effects or decreases the required dosages of each drug thereby reducing the severity of adverse effects (4). Thus, the search for combinations of agents that can achieve synergistic antitumor effects remains an important strategy with which to improve the effects of chemotherapy. Acetylation is a major form of protein post-translational modification and is responsible for regulating various cellular processes, including cell proliferation and cell survival (5). Acetylation is catalyzed by histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs transfer acetyl groups to lysine residues, whereas HDACs remove acetyl groups from lysine residues (6). In total, 18 human HDACs have been identified, which are categorized into four classes: Class I (HDAC1, HDAC2, HDAC3 and HDAC8), IIa (HDAC4, HDAC5, HDAC7 and HDAC9), IIb (HDAC6 and 10) and IV (HDAC11) are classical HDACs, whose activities are inhibited by pan-HDAC inhibitors, such as trichostatin A; whereas class III HDACs, also known as sirtuins, are not affected by trichostatin A (7). HDACs are overexpressed in many types of tumors, and inhibition of HDACs can result in the inhibition of cell proliferation and induction of apoptosis (8). HDAC inhibitors can achieve antitumor effects through the phosphatase and tensin homolog (PTEN)/protein kinase B (AKT) signaling pathway (9,10). To date, three pan-HDAC inhibitors, namely vorinostat (SAHA), belinostat (PXD-101) and panobinostat (LBH-589), have been approved by the US Food and Drug Administration (FDA) for the treatment of cancer (11). Clinical application of pan-HDAC inhibitors can result in several adverse side-effects, such as fatigue, diarrhea, bone marrow toxicity and thrombocytopenia (12). This is likely due to the fact that most HDACs are necessary for important biological processes; knockout of HDAC1, or most other Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN GUANHUA ZHANG1,2 and YE-HUA GAN1,2 1Central Laboratory and 2Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Haidian, Beijing 100081, P.R. China Received March 15, 2017; Accepted August 11, 2017 DOI: 10.3892/or.2017.5981 Correspondence to: Dr Ye-Hua Gan, Central Laboratory, Peking University School of Stomatology, 22 Zhongguancun Avenue South, Haidian, Beijing 100081, P.R. China E-mail: kqyehuagan@bjmu.edu.cn

AKT activation controls cell survival in response to HDAC6 inhibition

The Cytoplasmic Deacetylase HDAC6 is Required for Efficient Oncogenic Tumorigenesis

Synergistic Antitumor Effects of the Combined Treatment with an HDAC6 Inhibitor and a COX-2 Inhibitor Through Activation of PTEN

Abstract 4582: HDAC6 inhibition reshapes the epigenome of cancer via P300 stabilization

HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.

PTEN Activation Through K163 Acetylation by Inhibiting HDAC6 Contributes to Tumour Inhibition

Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy

Dna-Pkcs Inhibition Impairs Hdac6-Mediated Hsp90 Chaperone Function On Aurora A And Enhances Hdacs Inhibitor-Induced Cell Killing By Increasing Mitotic Aberrant Spindle Assembly

Histone deacetylase 6 in cancer

Novel Histone Deacetylase (HDAC) Inhibitor Induces Apoptosis and Suppresses Invasion via E-Cadherin Upregulation in Pancreatic Ductal Adenocarcinoma (PDAC)

HDAC6-dependent Deacetylation of AKAP12 Dictates Its Ubiquitination and Promotes Colon Cancer Metastasis.

tion of histone deacetylase 6 (HDAC6) inhibitor tubastatin A together with cyclooxygenase-2 (COX-2) inhibitor celecoxib resulted in synergistic antitumor effects in CAL 27 and SACC-83 cells. Treatment with celecoxib alone promoted the membrane translocation of phosphatase and tensin homolog (PTEN),

An Acetyl-Histone Vulnerability in PI3K/AKT Inhibition-Resistant Cancers is Targetable by Both BET and HDAC Inhibitors

HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.

Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling Through TRIM24 Binding.

C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α -tubulin hyperacetylation both in vitro and in vivo

PTK6 Regulates IGF-1-Induced Anchorage-Independent Survival

HDAC6 Interacts with PTPN1 to Enhance Melanoma Cells Progression.

ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy